These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36211350)

  • 1. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.
    Su K; Guo L; Ma W; Wang J; Xie Y; Rao M; Zhang J; Li X; Wen L; Li B; Yang X; Song Y; Huang W; Chi H; Gu T; Xu K; Liu Y; Chen J; Wu Z; Jiang Y; Li H; Zeng H; Wang P; Feng X; Chen S; Yang B; Jin H; He K; Han Y
    Front Immunol; 2022; 13():972503. PubMed ID: 36211350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
    Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
    BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study.
    Hsu S; Chao Y; Hu Y; Zhang Y; Hong W; Chen Y; Chen R; Zeng Z; Du S
    Chin Med J (Engl); 2024 Jun; 137(11):1332-1342. PubMed ID: 38725345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
    Byun HK; Kim HJ; Im YR; Kim DY; Han KH; Seong J
    Radiother Oncol; 2019 Apr; 133():1-8. PubMed ID: 30935563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
    J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
    Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.
    Wang XH; Liu CJ; Wen HQ; Duan XH; Jiao YQ; Liu YJ; Chen MS; Zhu KS; Mao XH; Zhou QF
    Clin Transl Med; 2023 Mar; 13(3):e1214. PubMed ID: 36855781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
    JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high-risk: A propensity score matching study.
    Zuo M; Zheng G; Cao Y; Lu H; Li D; An C; Fan W
    Int J Surg; 2024 Jul; ():. PubMed ID: 38995173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center retrospective study on the efficacy and safety of regorafenib
    Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
    Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis.
    Ma J; Zhang H; Zheng R; Wang S; Ding L
    Oncologist; 2024 Sep; ():. PubMed ID: 39231443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
    Qin J; Huang Y; Zhou H; Yi S
    Front Oncol; 2022; 12():807102. PubMed ID: 35463356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma.
    Byun HK; Kim HJ; Im YR; Kim DY; Han KH; Seong J
    Strahlenther Onkol; 2020 Feb; 196(2):132-141. PubMed ID: 31286149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis.
    Wang X; Liu G; Chen S; Bi H; Xia F; Feng K; Ma K; Ni B
    Int J Hyperthermia; 2021 Oct; 38(1):1519-1528. PubMed ID: 34702122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
    Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P; Pi X; Gao F; Li Q; Li D; Feng W; Cao W
    Front Oncol; 2022; 12():945915. PubMed ID: 36338683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.